使用交织镍钛合金支架行血管内血运重建治疗股总动脉疾病的多中心注册研究:一项观察性回顾性研究
该回顾性多中心注册研究分析了2019至2021年间因股总动脉病变接受交织镍钛合金支架血管内治疗的症状性下肢动脉疾病患者,共纳入177例患者196处股总动脉病变。2年无再狭窄率为88.0%,靶病变血运重建、大截肢和全因死亡的2年免除率分别为92.9%、99.0%和75.2%。参考血管直径、髂外动脉受累、股浅动脉受累、体重指数、基线股深动脉闭塞及慢性肢体威胁性缺血与再狭窄风险显著相关。
要点
- 股总动脉病变使用交织镍钛合金支架行血管内治疗2年无再狭窄率为88.0%。
- 2年大截肢免除率为99.0%,靶病变血运重建免除率为92.9%。
- 中位随访12.0个月期间73例(37.2%)经植入支架的股总动脉置入导引导管,无穿刺相关并发症。
核心结论
- 使用交织镍钛合金支架对股总动脉病变行血管内治疗显示出可接受的2年通畅率88.0%,并可能保留经同侧股总动脉的动脉入路。
- 参考血管直径小、髂外动脉和股浅动脉病变受累、消瘦、股深动脉闭塞及慢性肢体威胁性缺血与血管内治疗后较差的2年通畅率相关,因此对于不适合外科血运重建的患者,股总动脉病变植入交织镍钛合金支架可能是一种选择。
研究设计与样本
- 回顾性多中心注册研究,分析2019至2021年间因股总动脉病变导致症状性下肢动脉疾病并接受交织镍钛合金支架血管内治疗的患者,共纳入177例患者196处股总动脉病变。
主要发现
- 2年无再狭窄估计值为88.0%,靶病变血运重建、大截肢和全因死亡的2年免除率分别为92.9%、99.0%和75.2%。
- 与再狭窄风险显著相关的临床特征包括:参考血管直径(每增加1.0 mm,HR 0.24 [0.08-0.70],p=0.009)、髂外动脉受累(HR 4.03 [1.56-10.4],p=0.004)、股浅动脉受累(HR 3.05 [1.00-9.25],p=0.049)、体重指数(每增加1.0,HR 0.85 [0.73-0.99],p=0.032)、基线股深动脉闭塞(HR 7.89 [2.04-30.5],p=0.003)及慢性肢体威胁性缺血(HR 2.63 [1.02-6.78],p=0.045)。
- 随机生存森林分析也证实了上述因素的显著关联。
- 中位随访12.0个月期间,73例(37.2%)经植入交织镍钛合金支架的股总动脉置入导引导管,无患者发生穿刺相关并发症,如止血失败、交织镍钛合金支架断裂和支架闭塞。
临床怎么用
- 作者认为,对于不适合外科血运重建的患者,股总动脉病变植入交织镍钛合金支架可能是一种选择。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Surgical thromboendarterectomy has been the gold standard treatment for common femoral artery (CFA) disease. However, endovascular therapy (EVT) is conducted in certain patients with CFA lesions because of multiple comorbidities. The interwoven nitinol stent (IWS) has been developed to prevent stent fracture. Thus, this study aimed to evaluate the feasibility of EVT using IWS for CFA lesions in clinical practice. MATERIALS AND METHODS: This retrospective multicenter registry analyzed patients who had symptomatic lower-extremity artery disease due to CFA lesions and underwent EVT using IWS between 2019 and 2021. The primary endpoint was restenosis 2 years after EVT. RESULTS: This study enrolled a total of 177 patients with 196 CFA lesions. The 2-year estimate of freedom from restenosis was 88.0%. The 2-year freedom rates from the target-lesion revascularization, major amputation, and all-cause death were 92.9%, 99.0%, and 75.2%, respectively. The clinical features significantly associated with restenosis risk were the reference vessel diameter (RVD, per 1.0 mm, hazard ratio [HR], 0.24 [0.08-0.70]; p=0.009), external iliac artery (EIA) involvement (HR=4.03 [1.56-10.4]; p=0.004), superficial femoral artery (SFA) involvement (HR=3.05 [1.00-9.25]; p=0.049), body mass index (BMI; per 1.0, HR=0.85 [0.73-0.99]; p=0.032), occlusion of deep femoral arteries (DFAs) at baseline (HR=7.89 [2.04-30.5]; p=0.003), and chronic limb-threatening ischemia (CLTI, HR=2.63 [1.02-6.78]; p=0.045). Their significant association was also confirmed by the random survival forest analysis. During a median follow-up of 12.0 months, guiding sheaths were inserted via CFAs implanted IWSs in 73 cases (37.2%), and no patients had cannulation-related complications, such as failed hemostasis, fracture of IWS, and stent occlusion. CONCLUSIONS: Endovascular therapy using IWS in CFA lesions showed acceptable 2-year patency rates at 88.0% and might preserve the arterial access via the ipsilateral CFAs. Small RVD, involving EIA and SFA lesions, emaciation, occluded DFA, and CLTI are associated with poor 2-year patency rates following EVT, thus, IWS implantation in CFA lesions may be an option for patients unsuitable for surgical revascularization.Clinical ImpactThis retrospective multicenter registry enrolled 177 patients with 199 CFA lesions treated with EVT using interwoven nitinol stents, because surgical thromboendarterectomy was difficult due to their multiple comorbidities. The 2-year estimate of freedom from restenosis was acceptable at 88.0%. The 2-year freedom rate from major amputation was also high at 99.0%. Moreover, during a median follow-up of 12.0 months, guiding sheaths were inserted via CFAs implanted IWSs in 73 cases, and no patients had cannulation-related complications such as failed hemostasis, fracture of IWS, and stent occlusion.
引用
- Horie K, Takahara M, Nakama T, et al. Multicenter Registry of Common Femoral Artery Disease Treated With Endovascular Revascularization Using Interwoven Nitinol Stents: An Observational Retrospective Study. J Endovasc Ther. 2024. PMID: 38369732. doi:10.1177/15266028241231472
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。